JP2019535785A5 - - Google Patents

Info

Publication number

JP2019535785A5

JP2019535785A5 JP2019528489A JP2019528489A JP2019535785A5 JP 2019535785 A5 JP2019535785 A5 JP 2019535785A5 JP 2019528489 A JP2019528489 A JP 2019528489A JP 2019528489 A JP2019528489 A JP 2019528489A JP 2019535785 A5 JP2019535785 A5 JP 2019535785A5

Authority

JP

Japan

Prior art keywords

composition according

insulin

subject

mace

disease

Prior art date

2017-11-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 18
• 239000000203 mixture Substances 0.000 claims 17
• 102000004877 Insulin Human genes 0.000 claims 9
• 108090001061 Insulin Proteins 0.000 claims 9
• 229940125396 insulin Drugs 0.000 claims 9
• 238000011282 treatment Methods 0.000 claims 6
• 208000024172 Cardiovascular disease Diseases 0.000 claims 3
• 208000020832 chronic kidney disease Diseases 0.000 claims 3
• 238000003384 imaging method Methods 0.000 claims 3
• 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
• 206010020772 Hypertension Diseases 0.000 claims 2
• 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
• 206010027525 Microalbuminuria Diseases 0.000 claims 2
• 208000031481 Pathologic Constriction Diseases 0.000 claims 2
• 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
• 210000003423 ankle Anatomy 0.000 claims 2
• 230000036772 blood pressure Effects 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims 2
• 229960004225 insulin degludec Drugs 0.000 claims 2
• 239000005022 packaging material Substances 0.000 claims 2
• 201000001474 proteinuria Diseases 0.000 claims 2
• 238000012216 screening Methods 0.000 claims 2
• 208000037804 stenosis Diseases 0.000 claims 2
• 230000036262 stenosis Effects 0.000 claims 2
• 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
• 208000019553 vascular disease Diseases 0.000 claims 2
• 230000002861 ventricular Effects 0.000 claims 2
• 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
• JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims 1
• 206010019280 Heart failures Diseases 0.000 claims 1
• 108010057186 Insulin Glargine Proteins 0.000 claims 1
• FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 1
• COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 1
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
• 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
• 230000002411 adverse Effects 0.000 claims 1
• 239000003472 antidiabetic agent Substances 0.000 claims 1
• 229940125708 antidiabetic agent Drugs 0.000 claims 1
• 230000008321 arterial blood flow Effects 0.000 claims 1
• 210000001367 artery Anatomy 0.000 claims 1
• 230000000747 cardiac effect Effects 0.000 claims 1
• 230000007211 cardiovascular event Effects 0.000 claims 1
• 208000026106 cerebrovascular disease Diseases 0.000 claims 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
• 230000008602 contraction Effects 0.000 claims 1
• 230000001934 delay Effects 0.000 claims 1
• 229960001089 dobutamine Drugs 0.000 claims 1
• 230000024924 glomerular filtration Effects 0.000 claims 1
• 208000019622 heart disease Diseases 0.000 claims 1
• 108010050259 insulin degludec Proteins 0.000 claims 1
• 229960002869 insulin glargine Drugs 0.000 claims 1
• 230000007774 longterm Effects 0.000 claims 1
• 210000003141 lower extremity Anatomy 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 208000031225 myocardial ischemia Diseases 0.000 claims 1
• 238000012633 nuclear imaging Methods 0.000 claims 1
• 239000003538 oral antidiabetic agent Substances 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1
• 229940068196 placebo Drugs 0.000 claims 1
• 239000000902 placebo Substances 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1